Opinion

Video

Emerging Agents in IPF Treatment

Author(s):

Steven D. Nathan, MD

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.

Video content above is prompted by the following:

  • There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF). Which are you most excited about? What is the potential impact these agents, if approved, could have on the IPF treatment landscape?
Related Videos
Dr Geoffrey Rutledge
3 experts are featured in this series.
5 experts are featured in this series
4 experts are featured in this series.
4 experts are featured in this series.
5 experts are featured in this series
1 expert is featured in this series.
3 experts are featured in this series.
Related Content
Clinician documentation | Image Credit: - DC Studio - stock.adobe.com
March 26th 2025

Speech Recognition Tools May Boost Clinician Documentation Efficiency

Brooke McCormick
Documentation efficiency was higher among younger and male clinicians.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
FDA approval graphic | Image Credit: wladimir1804 - stock.adobe.com
March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.
Woman affected by blurry vision | Image Credit: Prostock-studio - stock.adobe.com
March 25th 2025

Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer

Brooke McCormick
New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) for patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo